1h Free Analyst Time
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Drugs In Development, 2021, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape. Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.Speak directly to the analyst to clarify any post sales queries you may have.
Report Highlights
This pipeline guide provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 7, 30, 37, 1, 4, 145, 59 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 53 and 13 molecules, respectively.
Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders)
- The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
- The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects
- The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects
- The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders)
- Classify potential new clients or partners in the target demographic
- Develop tactical initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
- Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionAppendix
Obesity - Overview
List of Tables
List of Figures
Companies Mentioned
A selection of companies mentioned in this report includes:
- 9 Meters Biopharma Inc
- Aardvark Therapeutics Inc
- Adare Pharma Solutions
- Adipo Therapeutics LLC
- Adocia SAS
- Agentix Corp
- AgeX Therapeutics Inc
- Alla Chem LLC
- Altimmune Inc
- Amgen Inc
- Anagenesis Biotechnologies SAS
- Antag Therapeutics ApS
- AntiCancer Inc
- Aoxing Pharmaceutical Company Inc
- Applied Molecular Transport Inc
- AptamiR Therapeutics Inc
- Aptorum Group Ltd
- AstraZeneca Plc
- August Therapeutics Inc
- Auris Medical Holding Ltd
- Autotac Bio Inc
- Betagenon AB
- BioRestorative Therapies Inc
- Biozeus Pharmaceutical SA
- Boehringer Ingelheim International GmbH
- Braasch Biotech LLC
- Bristol-Myers Squibb Co
- Bukwang Pharmaceutical Co Ltd
- Caliway Biopharmaceutics Co Ltd
- Callitas Therapeutics Inc
- Can-Fite BioPharma Ltd
- Carmot Therapeutics Inc
- Cellivery Therapeutics Inc
- Centeer BioTherapeutics Ltd Co
- CinFina Pharma LLC
- Circadian Therapeutics
- CK Biotech Inc
- Clayton Biotechnologies Inc
- CohBar Inc
- Corbus Pharmaceuticals Inc
- Corcept Therapeutics Inc
- Courage Therapeutics Inc
- CURx Pharmaceuticals Inc
- CVI Pharmaceuticals US Inc
- Cyrus Therapeutics Inc
- D&D Pharmatech Co Ltd
- Daewoong Pharmaceutical Co Ltd
- DD Therapeutics LLC
- Diasome Pharmaceuticals Inc
- DiscoveryBiomed Inc
- Dompe Farmaceutici SpA
- Eccogene (Shanghai) Co Ltd
- Elevian Inc
- Eli Lilly and Co
- Empros Pharma AB
- EncuraGen Inc
- Energesis Pharmaceuticals Inc
- Enspire Bio Inc
- Enterin Inc
- Eolo Pharma
- EraCal Therapeutics AG
- ERX Pharmaceuticals Inc
- Eternygen GmbH
- FGH BioTech Inc
- Fzata Inc
- Gan & Lee Pharmaceuticals Co Ltd
- Gila Therapeutics Inc
- Glaceum Inc
- Glucox Biotech AB
- Gmax Biopharm LLC
- GPER G-1 Development Group LLC
- Guangzhou BeBetter Medicine Technology Co Ltd
- Gubra ApS
- Gusto Global LLC
- HanAll Biopharma Co Ltd
- Hangzhou Adamerck Pharmlabs Inc
- Hangzhou Jiuyuan Gene Engineering Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- HEC Pharma Co Ltd
- Huadong Medicine Co Ltd
- Ildong Pharmaceutical Co Ltd
- Immungenetics AG
- ImmunoBiome Inc
- Infusion Biosciences
- Innovimmune Biotherapeutics Inc
- Intarcia Therapeutics Inc
- Japan Tobacco Inc
- Jenrin Discovery Inc
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd
- Johnson & Johnson
- Kallyope Inc
- KinDex Pharmaceuticals Inc
- Kissei Pharmaceutical Co Ltd
- Kriya Therapeutics Inc
- Kwang Dong Pharmaceutical Co Ltd
- Lead Discovery Center GmbH
- LG Chem Ltd
- Lipidio Pharmaceuticals Inc
- Lixte Biotechnology Holdings Inc
- MAKScientific LLC
- MD Healthcare Inc
- MeiraGTx Holdings Plc
- Merck & Co Inc
- Muen (Guangzhou) Biological Technology Co Ltd
- Nano Intelligent Biomedical Engineering Corp
- NeonMind Biosciences Inc
- NeuroNano Pharma Inc
- NGM Biopharmaceuticals Inc
- NIMIUM Therapeutics Inc
- Nordic Bioscience AS
- Novartis AG
- NovMetaPharma Co Ltd
- Novo Nordisk AS
- Nubiyota LLC
- NuSirt Biopharma Inc
- ObeTherapy Biotechnology
- Ochre Bio Ltd
- Omeros Corp
- Onegene Biotechnology Inc
- OPKO Health Inc
- Oramed Pharmaceuticals Inc
- Orbit Discovery Ltd
- Otsuka Holdings Co Ltd
- Oxt Therapeutics Inc
- Palatin Technologies Inc
- PegBio Co Ltd
- Pfizer Inc
- Preveceutical Medical Inc
- Primetime Life Sciences LLC
- Pylum Biosciences Inc
- Qoracle Co Ltd
- Raziel Therapeutics
- Regeneron Pharmaceuticals Inc
- Renova Therapeutics Inc
- Repurpose.AI Inc
- Resalis Therapeutics Srl
- Reviva Pharmaceuticals Inc
- Rhamnopharma Inc
- Rhythm Pharmaceuticals Inc
- RosVivo Therapeutics Inc
- Saniona AB
- Sanofi
- Scioto Biosciences Inc
- Sciwind Biosciences Co Ltd
- Scohia Pharma Inc
- Senda Biosciences Inc
- Seres Therapeutics Inc
- Shanghai Fosun Pharmaceutical (Group) Co Ltd
- Shionogi & Co Ltd
- Sigrid Therapeutics AB
- Siragen Pharmaceuticals Inc
- SJT Molecular Research SL
- SK Plasma Co Ltd
- Slate Bio Inc
- Soleno Therapeutics Inc
- Sun Pharmaceutical Industries Ltd
- Takeda Pharmaceutical Co Ltd
- Techfields Pharma Co Ltd
- Tryp Therapeutics Inc
- UGISense AG
- Uni-Bio Science Group Ltd
- Velabs Therapeutics GmbH
- Virtici LLC
- Vivus Inc
- XL-protein GmbH
- YSOPIA Bioscience SA
- Yuhan Corp
- Zealand Pharma AS
- Zhejiang Doer Biologics Corp
- Zihipp Ltd
- Zylem Biosciences Inc